{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-064847","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.903772+00:00","generated_at":"2026-05-16T00:59:49.393498+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan","bullets":["Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.","Aptose enters $11.1M second amended facility with Hanmi; advances capped at $2M each, 6% interest, matures May 31, 2026.","Facility funds clinical development of Tuspetinib for AML triplet therapy.","Arrangement agreement restated to update meeting date; board unanimously recommends shareholders vote FOR.","Facility is a related-party transaction exempt from formal valuation/minority approval due to financial hardship."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-064847","json":"https://secwatch.observer/filing/0001193125-26-064847.json","markdown":"https://secwatch.observer/filing/0001193125-26-064847.md","text":"https://secwatch.observer/filing/0001193125-26-064847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/0001193125-26-064847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/d70162d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:59:49.393498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4993285777533a51e9f4dd59bd6b93e38105d28","claim":"Aptose Biosciences Inc. amended credit facility of US$11.1 million with Hanmi Pharmaceuticals Co. Ltd. at six percent (6%) per annum.","evidence_excerpt":"Second Amended and Restated Facility Agreement On February 23, 2026, the Company and Hanmi entered into a US$11.1 million second amended and restated facility agreement with Hanmi (the “ Second A&R Facility Agreement ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312526064847/0001193125-26-064847-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"US$11.1 million"},{"label":"Counterparty","value":"Hanmi Pharmaceuticals Co. Ltd."},{"label":"Rate","value":"six percent (6%) per annum"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}